title: [Colorectal neo- and dysplasia in acromegaly].
abstract: Colorectal disorders can be not only an independent disease, but also manifestation of acromegaly--a neuroendocrine disease which is characterized by chronic pathological hypersecretion of the growth hormone (GH) and the increased concentration of insulino-like growth factor type 1 (IGF-1). In clinical recommendations on diagnosis and treatment of acromegaly, colonic polyps are marked as one of most pathognomonic manifestations of acromegaly. Prevalence of coloni polyps in acromegalic is 2,5-3 times higher than in the general population. Moreover, frequency of diverticula and dolichocolon is increased in patients with acromegaly compared with general population (in 3,6 and 12 times, accordingly). Colorectal cancer incidence with a tendency to more aggressive current is also increased (by 4,4 times). When these colonic diseases is diagnosed, especially in patients of young age, it is necessary to define the IGF-1 blood level as the first stage of acromegaly identification. If diagnosis of acromegaly is confirmed, gastroenterologist with endocrinologist together should direct treatment on correction of intestinal pathology as well as on achievement of the biochemical control over acromegaly.
authors.forename: I A
authors.initials: IA
authors.lastname: Ilovaĭskaia
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology*; D011125:Adenomatous Polyposis Coli / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control; D015179:Colorectal Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000517:prevention & control; D004241:Diverticulum, Colon / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis*; D015282:Octreotide / Q000008:administration & dosage / Q000627:therapeutic use; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000627:therapeutic use; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D015282:Octreotide